The story of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, producing billions in income, its intellectual property lapse created a deluge of knock-off medications, significantly impacting its dominance. While specific businesses may attempt to capitalize on male sexual dysfun